Momélotinib en traitement de première ligne ou en seconde ligne après le ruxolitinib chez les patients atteints de myélofibrose primitive ou secondaire

IF 1.1 4区医学 Q4 ONCOLOGY

Bulletin Du Cancer Pub Date : 2024-09-01 DOI:10.1016/j.bulcan.2024.04.010

引用次数: 0

查看原文本刊更多论文

[原发性或继发性骨髓纤维化患者将莫美洛替尼作为鲁索利替尼治疗后的一线或二线治疗】。］

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bulletin Du Cancer 医学-肿瘤学

CiteScore

1.90

自引率

16.70%

发文量

224

审稿时长

37 days

期刊介绍： Without doubt, the ''Bulletin du Cancer'' is the French language publication of reference in the field of cancerology. Official organ of the French Society of Cancer, this journal covers all the information available, whether in the form of original articles or review articles, but also clinical cases and letters to the editor, including various disciplines as onco-hematology, solids tumors, medical oncology, pharmacology, epidemiology, biology as well as fundamental research in cancerology. The journal proposes a clinical and therapeutic approach of high scientific standard and regular updates in knowledge are thus made possible. Articles can be submitted in French or English.